ORKA

Company Overview — What Does Oruka Therapeutics, Inc. Do?

Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Our mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice per year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. Oruka Therapeutics, Inc. (ORKA) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Lawrence Klein, headquartered in WESTMINSTER, California. With a market capitalization of $2.5B, ORKA is one of the notable companies in the Healthcare sector.

Oruka Therapeutics, Inc. (ORKA) Stock Rating — Hold (April 2026)

As of April 2026, Oruka Therapeutics, Inc. receives a Hold rating with a composite score of 38.0/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.ORKA ranks #1,472 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Oruka Therapeutics, Inc. ranks #124 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ORKA Stock Price and 52-Week Range

Oruka Therapeutics, Inc. (ORKA) currently trades at $59.32. The stock lost $4.28 (6.7%) in the most recent trading session. The 52-week high for ORKA is $42.88, which means the stock is currently trading 38.3% from its annual peak. The 52-week low is $5.49, putting the stock 981.5% above its annual trough. Recent trading volume was 1.0M shares, reflecting moderate market activity.

Is ORKA Overvalued or Undervalued? — Valuation Analysis

Oruka Therapeutics, Inc. (ORKA) carries a value factor score of 28/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 6.36x, versus the sector average of 2.75x.

At current multiples, Oruka Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Oruka Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Oruka Therapeutics, Inc. (ORKA) earns a quality factor score of 28/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -22.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -21.4% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ORKA Debt, Balance Sheet, and Financial Health

Oruka Therapeutics, Inc. has a debt-to-equity ratio of 4.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 22.37x, indicating strong short-term liquidity.

ORKA has a beta of 1.12, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Oruka Therapeutics, Inc. is 30/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Oruka Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Oruka Therapeutics, Inc. reported revenue of $0. Net income for the quarter was $-104M. Operating income came in at $-117M.

In FY 2025, Oruka Therapeutics, Inc. reported revenue of $0. Net income for the quarter was $-105M. Operating income came in at $-122M.

In Q3 2025, Oruka Therapeutics, Inc. reported revenue of $0. Net income for the quarter was $-30M. Operating income came in at $-34M.

In Q2 2025, Oruka Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.46. Net income for the quarter was $-25M. Operating income came in at $-28M.

Over the past 8 quarters, Oruka Therapeutics, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing ORKA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ORKA Dividend Yield and Income Analysis

Oruka Therapeutics, Inc. (ORKA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ORKA Momentum and Technical Analysis Profile

Oruka Therapeutics, Inc. (ORKA) has a momentum factor score of 77/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 6/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

ORKA vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Oruka Therapeutics, Inc. (ORKA) ranks #124 out of 838 stocks based on the Blank Capital composite score. This places ORKA in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ORKA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ORKA vs S&P 500 (SPY) comparison to assess how Oruka Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

ORKA Next Earnings Date

No upcoming earnings date has been announced for Oruka Therapeutics, Inc. (ORKA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ORKA? — Investment Thesis Summary

Oruka Therapeutics, Inc. presents a balanced picture with arguments on both sides. The quality score of 28/100 flags below-average profitability. The value score of 28/100 indicates premium valuation. Price momentum is positive at 77/100, suggesting the trend favors buyers. High volatility (stability score 30/100) increases portfolio risk.

In summary, Oruka Therapeutics, Inc. (ORKA) earns a Hold rating with a composite score of 38.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ORKA stock.

Related Resources for ORKA Investors

Explore more research and tools: ORKA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ORKA head-to-head with peers: ORKA vs AZN, ORKA vs SLGL, ORKA vs VMD.